Hospitalized Cardiovascular Diseases in Neovascular Age-Related Macular Degeneration

The Degge Group, Ltd, Arlington, Virginia, USA.
Archives of ophthalmology (Impact Factor: 4.4). 09/2008; 126(9):1280-6. DOI: 10.1001/archopht.126.9.1280
Source: PubMed


To compare the incidence rate of hospitalized myocardial infarctions (MIs) and cerebrovascular accidents (CVAs) in subjects with and without neovascular age-related macular degeneration (AMD).
A retrospective database cohort study was performed in subjects with neovascular AMD and controls matched for age, sex, geography, and enrollment duration. Healthcare claims for the study period from January 1, 2002, to June 30, 2005, were used to identify subjects and outcomes. Incidence of hospitalized MI and CVA events and rate ratios adjusted for 11 risk factors were calculated.
In 7203 subjects with neovascular AMD and 20,208 controls, the rate of MI was 16.2 events per 1000 subjects with neovascular AMD and 23.1 events per 1000 controls. The adjusted rate ratio for MI was 0.58 (95% confidence interval, 0.48-0.72; P < .001) for subjects with neovascular AMD vs controls. The rate of CVA was 14.3 events per 1000 subjects with neovascular AMD and 22.1 events per 1000 controls. The adjusted rate ratio for CVA was 0.56 (95% confidence interval, 0.45-0.70; P < .001).
Rates of MI or CVA were significantly lower in subjects with neovascular AMD than in controls. These findings could not be explained by systematic differences in case selection, health care use, or comorbidities, although other possible biases cannot be ruled out.

Download full-text


Available from: Emily West Gower
  • Source
    • "In the Australian Heart Eye Study (AHES)[50], researchers reported that the severity of coronary stenosis and the presence of stenotic lesions of CAD were independently associated with early AMD but showed no associations with late AMD. However, an inverse association was reported between nAMD and cardiovascular disease requiring hospitalization in a large casecontrol study[51], which was in accordance with our results. We found that CAD conferred an increased risk for PCV (OR 3.381, 95%CI 1.377–8.302) "
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To investigate the effect of genetic variants in the high-density lipoprotein (HDL) metabolic pathway and risk factors on neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) in China. Methods: A total of 742 Chinese subjects, including 221 controls, 230 cases with nAMD, and 291 cases with PCV, were included in the present study. Five single nucleotide polymorphisms (SNPs) from three genes in the HDL metabolic pathway (HDLMP) including cholesteryl ester transfer protein (CETP), hepatic lipase (LIPC) and lipoprotein lipase (LPL) were genotyped in all study subjects with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Risk factors including gender, hypertension, hyperlipidemia, diabetes mellitus, and coronary artery disease were identified. Chi-square tests or Fisher's exact tests were applied to discover associations between SNPs and risk factors for PCV and nAMD. Gene-gene interactions and gene-environment interactions were evaluated by the multifactor-dimensionality reduction (MDR) method. Results: CETP rs3764261 were significantly associated with an increased risk for PCV (odds ratio (OR) = 1.444, P = 0.0247). LIPC rs1532085 conferred an increased risk for PCV (OR = 1.393, P = 0.0094). We found no association between PCV and LPL rs12678919, LIPC rs10468017 or CETP rs173539. No association was found between five SNPs with nAMD. Regarding risk factors, females were found to have significantly decreased risks for both PCV and nAMD (P = 0.006 and 0.001, respectively). Coronary artery disease (CAD) was a risk factor in PCV patients but played a protective role in nAMD patients. Hyperlipidemia was associated with PCV but not with nAMD. Neither hypertension nor diabetes mellitus was associated with PCV or nAMD. The MDR analysis revealed that a three-locus model with rs12678919, rs1532085, and gender was the best model for nAMD, while a five-locus model consisting of rs10468017, rs3764261, rs1532085, gender, and hyperlipidemia was best for PCV. Conclusion: Our large-sample study suggested that CETP rs3764261 conferred an increased risk for PCV. We also first found the association between rs1532085 and PCV. The result of present study also showed that gender and CAD are associated with PCV and nAMD. Significant association was found between hyperlipidemia and PCV but not nAMD.
    Full-text · Article · Dec 2015 · PLoS ONE
  • Source
    • "This retrospective and nonrandomized study found that systemic adverse events occurred in 7 of the 503 patients (1.4%) in the bevacizumab group and in 3 of the 199 patients in the ranibizumab group (1.5%); this was not a significant difference. The event rates that we observed are similar to previously reported findings (13-15). Although the 2 groups in our study differed with respect to age and concomitant diseases such as diabetes mellitus and dyslipidemia, they were similar in terms of systemic adverse events even after adjusting for these factors. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to compare the incidence of systemic adverse events in patients treated with intravitreal injections of bevacizumab or ranibizumab, and to evaluate whether compared to ranibizumab administration, bevacizumab constitutes a higher risk for systemic adverse events. A retrospective review was conducted for 916 consecutive patients treated with at least 1 intravitreal injection of bevacizumab or ranibizumab. Cox regression was performed to assess whether a variable had predictive value for occurrence of new systemic adverse events and to account for different follow-up times. A total of 702 patients were analyzed; 503 patients received bevacizumab alone, and 199 patients received ranibizumab alone. Systemic adverse events occurred in 10 of 702 patients (1.4%): 7 in the bevacizumab group (7/503; 1.4%) and 3 in the ranibizumab group (3/199; 1.5%). This difference was not statistically significant (Fisher's exact test, P = 0.573). Cox proportional hazards analysis of 4 models did not reveal a covariate that significantly changed the hazard for systemic adverse events. In conclusion, compared to ranibizumab, bevacizumab may not increase the risk of systemic adverse events in patients receiving intravitreal injections.
    Full-text · Article · Dec 2012 · Journal of Korean medical science
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Even moderate exposures of ambient light can impose a threat to human retina and the retinal pigment epithelium – under particular preconditions. Repetitive light-stress implicates reversible phototoxic damage thereby paving the way towards age related macular degeneration (AMD) via temporal summation. Aggravating and interacting prerequisites like genotype/complement factors, smoking, nanomaterials (NM) and obstructive sleep disorders (OSA) as well as other factors "reflective of nature and nurture" [97, 98] eventually impact on the severity of retinal light damage linked to possible formation and progression of AMD. Unter gewissen Voraussetzungen können mäßige, scheinbar nicht überdosierte Licht – Belastungen Schäden der Netzhaut verursachen. Genotyp/Komplement-System, Rauchen, Stoffwechsel-Störungen, möglicherweise auch Schlaf-Apnoe und "Nano-Toxikologie" können in der Summe die Entstehung einer "alters-bedingten" Macula – Degeneration (AMD) auslösen und beschleunigen.
    Full-text · Article · Aug 2009 · Spektrum der Augenheilkunde
Show more